HNSAHansa Biopharma AB (publ)HNSA info
$3.85info-0.79%24h
Global rank
Market cap$202.10M
Change 7d-5.64%
YTD Performance62.09%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Hansa Biopharma AB (publ) (HNSA) Stock Overview

    Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

    HNSA Stock Information

    Symbol
    HNSA
    Address
    ScheelevAegen 22Lund, 223 63Sweden
    Founded
    -
    Trading hours
    -
    Website
    https://www.hansabiopharma.com
    Country
    πŸ‡ΈπŸ‡ͺ Sweden
    Phone Number
    46 46 16 56 70

    Hansa Biopharma AB (publ) (HNSA) Price Chart

    -
    Value:-

    Hansa Biopharma AB (publ) Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $3.85
    N/A
    Market Cap
    $202.10M
    N/A
    Shares Outstanding
    52.44M
    N/A
    Employees
    168.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org